All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
This article could contain syndicated content. We have not reviewed, approved, or endorsed the content and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
- Study participants had an 81%-98% reduction in annualized anti-VEGF injections and demonstrated continuous aflibercept expression levels through three years
- Mean best-corrected visual acuity and central subfield thickness were maintained or improved in subjects treated with ADVM-022
Read more at globenewswire.com| Symbol | Last | Chg | %Chg |
|---|---|---|---|
| ADVM | 2.43 | +0.21 | +9.46% |
| Adverum Biotechnologies Inc | |||
Please check your inbox for a link to activate your My Barchart Account.
If you do not receive the email within a few minutes check your spam folder or contact our support team for assistance.
/Alibaba%20by%20testing%20via%20Shutterstock.jpg)
